David Oxlade

Non-Executive Chairman

David is Chairman of the Board of tranScrip. He is a pharmaceutical professional with extensive experience in the global health care industry, having also worked at senior management and board level for six years in the USA and seven years in Asia.

David spent 14 years with Boehringer Mannheim and seven years (latterly as President) with California-based Syva, both now part of Roche. He led major innovations in health care, including a revolutionary home blood glucose monitoring for diabetics, creating the largest single diagnostic market segment and established Cellmark Diagnostics to commercialise the discovery of Prof. Alec Jeffreys, “DNA Fingerprinting”.

In 1998 he became CEO of Xenova, the LSE and NASDAQ listed biotech and in 2006 became Chairman of BioAnaLab, an analytical service company subsequently acquired in 2009 by Millipore Corporation. He is currently Chairman of base4innovation, a company developing rapid DNA sequencing systems, and also of Kirkstall, a private company which develops and markets advanced systems for cellular and toxicity testing, a Non-Executive Director of Oxford Cancer Biomarkers and previously a Non-Executive Director of Cobra Biomanufacturing.

David is an Honorary Fellow of Brunel University, has been a member of the Emerging Enterprise Council of EuropaBio and of the Bioscience Leadership Council, and chaired the European Working Group of the Bioscience Innovation and Growth Team (set up by UK Government under Sir David Cooksey to establish a 10 year agenda for the bioscience industry in the UK).